A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Exclusion Criteria

• •History of severe allergy or hypersensitivity to the investigational product or its excipients or drugs of similar chemical class (e.g., monoclonal antibodies), or contraindications to the investigational product.
• •Requirement for systemic immunosuppressive therapy within 14 days prior to the first dose of study drug or during the study.
• •Major surgery (excluding puncture biopsy) within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during this study.
• •Uncontrolled active brain metastases or leptomeningeal metastasis.
• •History of autoimmune disease requiring treatment with corticosteroids or immunosuppressive drugs.
• •Women in the period of preconception, pregnancy, or lactation.
• •Any other circumstances which the investigator considers may increase risks to subjects or interfere with the results of the trial.